(Q37605777)

21 August 2017

1 reference

title

Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer (English)

1 reference

21 August 2017

1 reference

1 reference

James E Frampton

1

1 reference

PubMed ID

19791830

21 August 2017

language of work or name

1 reference

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

69

1 reference

21 August 2017

15

1 reference

21 August 2017

2125-2148

1 reference

https://scigraph.springernature.com/pub.10.2165/11203240-000000000-00000

21 August 2017

0 references

cites work

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

12 December 2020

The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer

1 reference

12 December 2020

An overview of HER-targeted therapy with lapatinib in breast cancer

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

Overcoming endocrine therapy resistance by signal transduction inhibition

1 reference

12 December 2020

Effects of food on the relative bioavailability of lapatinib in cancer patients

1 reference

12 December 2020

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

12 December 2020

A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer

1 reference

12 December 2020

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

12 December 2020

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

1 reference

12 December 2020

Analysis of dermatologic events in patients with cancer treated with lapatinib.

1 reference

12 December 2020

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

1 reference

12 December 2020

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

1 reference

12 December 2020

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

12 December 2020

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

1 reference

12 December 2020

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

1 reference

12 December 2020

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

1 reference

12 December 2020

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

1 reference

12 December 2020

Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

12 December 2020

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

1 reference

12 December 2020

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

1 reference

12 December 2020

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

1 reference

12 December 2020

Integration of endocrine therapy with targeted agents

1 reference

12 December 2020

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

1 reference

12 December 2020

Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases

1 reference

12 December 2020

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

12 December 2020

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

1 reference

12 December 2020

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

1 reference

12 December 2020

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

12 December 2020

Lapatinib and ixabepilone for the treatment of metastatic breast cancer

1 reference

12 December 2020

Jumping higher: is it still possible? The ALTTO trial challenge

1 reference

12 December 2020

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

1 reference

12 December 2020

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

1 reference

12 December 2020

Lapatinib plus capecitabine in breast cancer

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

12 December 2020

Lapatinib-associated toxicity and practical management recommendations

1 reference

12 December 2020

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

12 December 2020

Lapatinib in breast cancer

1 reference

12 December 2020

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

1 reference

12 December 2020

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

1 reference

12 December 2020

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

12 December 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

12 December 2020

1 reference

12 December 2020

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

1 reference

12 December 2020

New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors

1 reference

12 December 2020

NICE's cost effectiveness threshold

1 reference

12 December 2020

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

12 December 2020

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

1 reference

12 December 2020

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

1 reference

12 December 2020

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

12 December 2020

HER-2-positive breast cancer: hope beyond trastuzumab

1 reference

12 December 2020

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer

1 reference

12 December 2020

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

1 reference

12 December 2020

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

1 reference

12 December 2020

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

12 December 2020

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

1 reference

12 December 2020

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

1 reference

12 December 2020

Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors

1 reference

12 December 2020

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

1 reference

12 December 2020

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies

1 reference

12 December 2020

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

12 December 2020

Lapatinib: current status and future directions in breast cancer

1 reference

12 December 2020

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

1 reference

12 December 2020

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

12 December 2020

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

1 reference

12 December 2020

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

1 reference

12 December 2020

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

1 reference

12 December 2020

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

1 reference

12 December 2020

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan

1 reference

12 December 2020

Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge

1 reference

12 December 2020

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

12 December 2020

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

1 reference

12 December 2020

10.2165/11203240-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

19791830

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

19791830